Articles

On August 11, 2023, the FDA accelerated the approval of the fixed-dose combination of niraparib and abiraterone acetate (Akeega; Janssen Biotech), with prednisone, for the treatment of adults with deleterious or suspected deleterious BRCA-mutated, castration-resistant prostate cancer, as determined by an FDA-approved test. The FDA granted this approval priority review.
Read More

On August 9, 2023, the FDA granted regular approval to pralsetinib (Gavreto; Genentech), a kinase inhibitor of wild-type RET and oncogenic RET fusions and mutations, for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) and RET fusion–positive gene mutation, as detected by an FDA-approved test.
Read More

Improving clinical outcomes in the second line of treatment in patients with advanced biliary tract cancer remains an important goal, and researchers have been exploring various therapeutic targets, including HER2, an oncogene that creates a protein that encourages cell growth and accelerates the spread of cancers.
Read More

It was once thought that after guiding the development of male sex organs in a fetus, the Y chromosome did not do much else. But over the past few years, results from multiple studies have challenged that belief.
Read More

Chicago, IL—Physicians are less likely to work in a private practice than 10 years ago due to economic, administrative, and regulatory burdens that have driven physicians to shift traditional business models for medical practices, according to a newly released biennial analysis of physician practice arrangements by the American Medical Association.
Read More

The American Society of Clinical Oncology has issued an update to its guidelines for the practical assessment and management of vulnerabilities in patients aged ≥65 years receiving systemic cancer treatment.
Read More

Opioids such as morphine are the gold standard for treating cancer-induced bone pain, but new University of Arizona Health Sciences research recently published in PAIN uncovered a mechanism by which chronic morphine use may increase bone loss and pain.
Read More

Medicine is an essential service. Yet, healthcare providers still need to make enough profit to cover their overhead costs if they want to keep their doors open. That is why it is essential for your business and community that claims are processed accurately and that you get reimbursed for your services.
Read More

Bringing Stakeholders Together Bringing Stakeholders Together
For executives like Andrew Hertler, MD, FACP, CMO, New Century Health, the annual AVBCC Educational Summit & Program is the single best conference for meeting with a large number of peers simultaneously.
Read More

Chicago, IL—It is well documented that clinical trials thus far have for the most part excluded underserved populations, and that means the results of these trials cannot be generalized to society at large. Fortunately, the federal government and medical societies have taken aim at remedying this imbalance in accrual for clinical trials.
Read More

Page 4 of 338